Mild radikal kemi för peptidmodifiering i sent skede

Mild radikal kemi för peptidmodifiering i sent skede

Vad "mildare" faktiskt betyder i detta sammanhang

Mild, i peptidkemi, är inte ett marknadsföringsadjektiv. Den kodar specifika driftsparametrar: pH 6–8, temperatur ≤ 37 °C, vattenkompatibla lösningsmedelssystem, och tolerans för hydroxyl, karboxyl, amino, tioeter, imidazol, och guanidiniumsidokedjor utan förskydd. Publicerade kriterier för biokonjugationskompatibilitet definierar i allmänhet detta intervall explicit, och den senaste tidens radikalkemilitteratur rapporterar allt oftare om experiment som utförts rakt av i den.

Mild radikal kemi för peptidmodifiering i sent skede

Som sagt, "mild" varierar fortfarande mellan transformationsklasserna som beskrivs nedan. Photoredox-metoder som använder organiska fotokatalysatorer och blå eller gröna lysdioder tenderar att vara de mest biokompatibla som standard. HAT-baserade kaskadmetoder och elektrokemiska C–H/S–H-kopplingsmetoder kan kräva hjälplösningsmedel (typiskt DMSO/vattenblandningar) vid förhållanden som påverkar lösligheten av längre eller mer aggregationsbenägna sekvenser. Regisserad C(sp³)–H aryleringsmetoder – särskilt de palladiumkatalyserade varianterna – inför ytterligare begränsningar kring att styra gruppinstallation och borttagning, som lägger till steg och potentiella föroreningskällor. Frågan för alla utvecklingsteam är inte om en metod är "mild i princip" utan om den är tillräckligt mild för den specifika sekvensen och nedströmsapplikationen.


Photoredox konjugation: Vad bevisen stöder

Photoredox-katalys har genererat den största och mest reproducerbara mängden av peptidfunktionaliseringsdata i sent skede. Kärnmekanismen — spännande en fotokatalysator med synligt ljus, genererar reaktiva radikalintermediärer vid definierade positioner, och koppla dem till radikala acceptorer eller partners - erbjuder kemoselektivitet genom den elektroniska selektiviteten hos den exciterade tillståndskatalysatorn snarare än genom skyddsgruppsmanövrar.

Mild radikal kemi för peptidmodifiering i sent skede

Tryptofan som det primära handtaget. C2-alkylering och C2-sulfenylering av tryptofan-innehållande peptider har båda visats under metallfria och fotokatalysatorfria förhållanden, den senare med användning av aryltianthreniumsalter. A 2023 rapportera in Organiska bokstäver (ACS, kemoselektiv funktionalisering i sent skede via fotokatalytisk C2-alkylering av tryptofan) beskriven funktionell grupptolerans kompatibel med oskyddat aspartat, glutamat, lysin, och serinsidokedjor - vilket är minimikravet för trovärdig funktionalisering av peptider i sen skede. A 2024 klickbar tryptofanmodifiering som beskrivs i Vetenskapens framsteg rapporteras katalysatorfri, sent stadium C2-sulfenylering tolerant mot fria cysteinrester, ett särskilt krävande test av kemoselektivitet.

Histidinalkylering. En C-H-alkylering av Minisci-typ i synligt ljus av histidininnehållande peptider med användning av 4-alkyl-1,4-dihydropyridiner som radikalprekursorer har rapporterats. Histidin är vanligtvis en problematisk rest i fotokemiska sammanhang på grund av dess oxidationskänslighet, så validerade metoder som är inriktade på imidazol C2- eller C5-positionen lägger till ett kemiskt distinkt handtag.

Dehydroalanin (Dha) som en mångsidig radikal acceptator. Dha installerad enzymatiskt eller genom kemisk omvandling från serin eller cystein fungerar som en radikalacceptor av Michael-typ under ett brett spektrum av förhållanden. A 2025 rapportera om platsselektiv konstruktion av N-länkade glykopeptider genom fotoredoxkatalys (PubMed) använde Dha som acceptor för N-glykosyloxamsyra-härledda radikaler under synligt ljus, som visar tillsats av Giese-typ utan att skydda kvarvarande glycin, alanin, eller serinrester närvarande. Utbytet och diastereoselektivitetssiffrorna i den studien - och frånvaron av en stereoselektiv lösning för Dha-radikala tillägg i många tidigare rapporter - belyser en ihållande klyfta: radikalt tillägg till Dha är ofta inte stereoretentivt, vilket har betydelse när a-kolkonfigurationen påverkar receptorbindning eller proteasstabilitet.

Dekarboxylativ konjugation. MacMillans grupp visade att det C-terminala karboxylatet av peptider kan selektivt oxideras och kopplas genom radikal dekarboxylering under blått ljus, utnyttjar skillnaden i oxidationspotential mellan interna och terminala karboxylater. This approach is mechanistically clean and avoids any side-chain preprotection, but it consumes the C-terminus — which limits its applicability unless a free C-terminus is expendable or the goal is terminal labeling.

Development note: Photoredox methods have demonstrated the broadest functional-group tolerance across the literature. The open questions for development use are reagent and photocatalyst removal, oxygen sensitivity during reaction and workup, and whether solvent systems (often DMSO/water) are compatible with downstream purification and lyophilization without introducing persistent residuals.


HAT och MHAT: Fjärraktivering utan förfunktionalisering

Hydrogen atom transfer (HATT) chemistry occupies a different niche from photoredox. Rather than targeting a predefined redox-active handle, HAT-based methods abstract hydrogen atoms from C(sp³)–H bonds to generate carbon-centered radicals at positions that would otherwise require directing groups or prefunctionalization. In the context of peptide modification, this primarily means two things: remote functionalization via 1,5-HAT relay processes and sequential cascade reactions combining radical generation with a second catalytic bond-forming step.

Peptidsyntes A 2025 paper in Organic Chemistry Frontiers (RSC, three-component alkylation of glycine derivatives and peptides via a site-selective 1,5-HAT cascade) demonstrated visible-light-mediated N-centered radical generation followed by 1,5-hydrogen atom transfer to the α-carbon of glycine residues, enabling a three-component alkylation. The selectivity arises from the geometry of the 1,5-shift rather than from electronic preference for any particular side chain, which has both advantages and limitations: the approach is broadly applicable to glycine-containing sequences but does not inherently distinguish between similarly positioned residues in longer chains.

Metal-assisted HAT, sometimes referred to in its cobalt- or iron-mediated forms as MHAT, brings additional control. The metal hydride generates a carbon radical under mild conditions — typically room temperature, hydrogen or silane as hydrogen source — and the resulting radical can be trapped by an alkene or radical acceptor in the same flask. For peptide application, the relevant question is whether the metal catalyst and hydrogen-source reagent are compatible with histidine, metionin, and cysteine side chains, all of which are potential competing reaction partners. Published precedent exists for simple dipeptide and tripeptide substrates; validation at longer chain lengths with multiple reactive side chains remains limited in the primary literature as of mid-2026.

Development note: HAT and MHAT methods are attractive for modifying sequences where a natural radical handle (Cys, Trp, Dha) is absent or must be preserved for biological activity. The site-selectivity challenge is real and sequence-dependent — a short peptide where selectivity looks excellent may behave differently in a 20-residue sequence with multiple competing abstractable positions.


C(sp³)–H Funktionalisering: Backbone-Adjacent Editing

Regisserad C(sp³)–H functionalization represents the most ambitious arm of this chemistry for peptide applications, targeting internal backbone-adjacent positions without a traditional reactive handle. Two approaches have demonstrated preparative-scale potential on peptide substrates.

Side-chain-directed arylation. A 2024 study from Hou et al. — summarized in a 2026 RSC review (recent advances in site-specific modifications of peptides and proteins) — reported β-C(sp³)–H arylation of internal positions in both linear and cyclic peptides using S-alkyl cysteine as the directing group and 2-pyridone as an auxiliary ligand, under palladium catalysis. The method achieved arylation at the β-carbon of the residue adjacent to the cysteine-derived directing group under exceedingly mild conditions for a palladium-catalyzed C–H activation.

Backbone-inserted directing groups. A 2025 rapportera in JACS (PubMed, Pd(II)-catalyzed C(sp³)–H functionalization directed by a removable, backbone-inserted amidoxime ether) described amidoxime ether insertion at any amide bond in the backbone, using it as a removable directing group for subsequent C(sp³)–H arylation. The amidoxime ether is installed and removed in separate synthetic steps, adding two transformations to the route — but the positional flexibility it provides has no equivalent in current standard modification approaches.

For sequence-agnostic positioning, this class is chemically significant. The practical burden — palladium removal, directing group installation and removal, SPPS-compatible protecting group compatibility, and potential epimerization at the α-carbon under palladium catalysis — is also the heaviest among the three transformation families discussed here.


Svavelbaserade radikala metoder: Kemoselektivitet med stöd av data

Cysteine remains the most analytically tractable residue for site-selective peptide modification because its sulfur nucleophilicity and redox chemistry are sufficiently distinct from other side chains to allow clean reactions with appropriate electrophilic radical sources. Several 2024–2025 reports extend this toolkit in directions relevant to conjugation programs.

Aryl radicals generated from aryl pinacol boronates under mild aqueous conditions have been shown to perform selective S-arylation of peptides and proteins (aryl radicals from aryl pinacol boronates for peptide and protein modification, TU Darmstadt/Wiley). The selectivity for sulfur over aromatic amino acid side chains under aqueous, near-neutral conditions represents a meaningful advance over aryl diazonium salt chemistry, which is far less selective.

An electrochemical approach to C–H/S–H cross-coupling for cysteine-containing peptides, including intramolecular macrocyclization, was described in Nature Communications (electro-induced C–H/S–H cross-coupling for functionalization/macrocyclization of cysteine-containing peptides, 2025). The umpolung strategy — generating a thiyl radical electrochemically and coupling it to an adjacent C–H bond — operates without external oxidant or photocatalyst and tolerates a range of side chains.

For programs involving stapled peptides, ADC-like conjugation, or fluorescence labeling at defined positions, these sulfur-selective methods represent the lowest-risk entry point because chemoselectivity data exists across the longest validated chain lengths and the most diverse side-chain environments.


Kompatibilitet, Förorening, och analytiska frågor som måste besvaras

The chemistry described above is real and reproducible at discovery scale. Translation to preparative and development scale requires honest answers to four categories of questions before any of these methods enter a formal development workflow.

Kompatibilitetsbedömning

Before committing to a late-stage radical modification route, development teams should map the following:

Compatibility dimension

What to determine

Varför det spelar roll

Solvent tolerance of the sequence

Does the peptide dissolve adequately in DMSO/water or DMSO-free conditions required?

Many radical methods favor DMSO-containing systems; aggregation-prone or hydrophobic sequences may precipitate

Side-chain competing reactions

Which side chains (Träffade, Trp, Tyr, Hans, Cys if not the target) can react under the chosen conditions?

A method validated on a simple model peptide may show new selectivity problems in a sequence with multiple sensitive residues

Buffer and pH sensitivity of the photocatalyst or radical precursor

Do co-additives (syra, bas, reductant) degrade Syntetiska peptider the peptide backbone or specific residues?

Even mild conditions can accelerate asparagine deamidation, aspartatisomerisering, or N→O acyl transfer at serine in extended reaction times

Oxygen sensitivity

Does the method require inert atmosphere at discovery scale? Peptidproduktion

Oxygen sensitivity that is manageable in a small glass vial becomes a reactor design and quality system question at preparative scale

Förutsägelse av föroreningsprofil

Late-stage radical modification introduces a class of impurities distinct from SPPS-derived impurities. Expect and plan analytical methods for:

  • Unreacted starting material: unconjugated peptide co-eluting with or near the product

  • Over-modified species: if more than one reactive site exists (till exempel, two tryptophan residues), multiple-modification products will appear as higher-mass signals on ESI-MS or MALDI-TOF

  • Regioisomeric products: for Dha radical addition or histidine alkylation, positional isomers that differ only in the site of bond formation may be analytically indistinguishable by RP-HPLC alone

  • Oxidation products: radical conditions can oxidize methionine to the sulfoxide or tryptophan to the oxindole — peaks that are structurally close to the starting material on reverse-phase chromatography

  • Catalyst-derived adducts: organic photocatalyst fragments, palladium residues (for C–H functionalization), or reagent by-products from HAT co-reagents that form adducts with the peptide

The regulatory and CMC implications of this impurity landscape align with the EMA’s Riktlinjer för utveckling och tillverkning av syntetiska peptider, which explicitly addresses process reagents, elemental impurities, and the control strategy for synthetic intermediates.

Analytiska krav

Standard RP-HPLC at 214 nm, which works well for SPPS impurity profiling, is insufficient for radical late-stage modification outputs. Teams should plan for:

  • LC-MS or LC-HRMS as the primary characterization tool — MS is required to distinguish unconjugated starting material from mono-modified product when they have similar chromatographic retention

  • Orthogonal chromatography modes (till exempel, HILIC or IEX in addition to RP) when regioisomers are anticipated; regioisomers with identical mass will not resolve by mass detection alone

  • Aminosyraanalys (AAA) for confirming that the amino acid composition after modification is consistent with a single addition event, not backbone cleavage or unusual side-chain loss

  • Stability-indicating methods that can distinguish synthesis impurities (present in the initial batch) from degradation products that appear over time — critical when a radical modification step introduces new chromophores or functional groups that alter the oxidation or hydrolysis stability profile of the peptide

Uppskalningsteknik

Photoredox methods present the most technically specific scale-up challenges because photon delivery does not scale linearly. The incident light intensity at the center of a 1-liter flask is a fraction of that at the vessel surface, and lamp-to-reactor geometry determines conversion in a way that has no analogue in thermally driven chemistry. Flow chemistry reactors designed for photocatalysis address this through thin-film or flow-through irradiation, and several validated reactor designs now exist for pharmaceutical process development — but they require upfront capital and method re-optimization at each scale step.

HAT and electrochemical methods have different scale-up profiles. Electrode surface area scales more predictably than photon delivery, but electrochemical methods introduce questions about electrode materials compatibility, electrolyte removal, and current density uniformity at preparative scale.

For all transformation classes, the transition from analytical-scale HPLC purification to preparative HPLC introduces additional resolution challenges. A late-stage modification product co-eluting with mono-modified regioisomers at analytical scale will require careful re-optimization of gradient slope, mobile phase composition, and column chemistry at preparative loading — and preparative HPLC recovery from a complex mixture is the rate-limiting step in peptide scale-up more often than the synthesis itself.


Ett ramverk för att utvärdera möjligheten att adoptera

Rather than adopting any of these methods wholesale, development teams should run a structured feasibility assessment tied to the specific modification target. The following decision matrix reflects the compatibility and risk dimensions discussed above.

Assessment question

Low-risk signal

Pause signal

Does the target residue exist as a single unique copy in the sequence?

Ja, with no structurally similar competing residue

Multiple potential sites of the same type

Is the modification site compatible with aqueous DMSO systems?

Sequence is soluble and non-aggregating in DMSO/H₂O

Hydrophobic sequence with documented aggregation in mixed solvents

Can catalyst or reagent residues be removed by existing RP-HPLC methods?

Ja, or precedent exists in the literature

No analytical precedent; novel adduct formation unclear

Does downstream application tolerate racemization risk?

Diastereomers at the modification site are both acceptable

Exact α-carbon configuration at the modified residue is required

Is the reaction compatible with inert atmosphere at target scale?

Ja, or flow chemistry infrastructure is available

Requires open-vessel chemistry at multi-gram scale without defined reactor solution

Passing the full checklist does not guarantee success — but it identifies which experiments to prioritize before committing development resources. A failed compatibility screen at the 5-milligram scale saves far more time than the same failure at 100 milligrams during a late CRO run.


Där konjugationsplattformar som redan finns tillgängliga kan hjälpa

Programs evaluating these newer methods alongside existing, validated modification approaches will naturally reference what their synthesis partner can execute without a custom process development phase. Peptide modification platforms that routinely handle click chemistry handles (azider, i schack, alkyner), glycopeptide installation, och fluorescent or isotope label conjugation already operate within the functional group tolerance envelope that radical late-stage methods are working to expand.

The value of the newer radical methods is not to replace these established conjugation routes — it is to access modification positions that classical chemistries cannot reach, particularly internal backbone positions and residues that lack convenient nucleophilic handles. When that capability is the bottleneck, a targeted radical functionalization method is worth the analytical and process development investment.

For everything else, etablerad anpassad peptidsyntes workflows with defined impurity acceptance criteria and validated analytical packages remain the faster path to a QC-released, development-ready batch.


Frågor som fältet ännu inte har besvarat

To close with an honest inventory: the 2024–2025 literature has established that mild radical chemistry works on peptides under discovery conditions. It has not yet established, for most methods:

  1. Skalbarhet: how conversion and selectivity behave at 100 milligrams versus 1 gram versus 100 grams under process-realistic conditions, with proper oxygen exclusion and temperature control

  2. Stereoselectivity at Dha: radical addition to dehydroalanine generates a new α-center with variable diastereomeric ratio; this is an open problem, and the recent ChemBioChem review (advances in dehydroalanine-specific modification, 2025) explicitly flags it as unresolved for most substrate classes

  3. Regulatory precedent: none of these routes has, to public knowledge, been the subject of a CMC IND section covering impurity qualification, genotoxic impurity assessment of photocatalyst residues, or stability-indicating method validation for radical-modified API — the groundwork remains to be laid

  4. Long-term stability of the modification bond: radical additions to Dha, Trp, and His create C–C, C–S, or C–N bonds with varying stability profiles; stability study data is sparse for most conjugates

These are not reasons to dismiss the chemistry. They are the experimental and regulatory program that must be designed alongside any decision to incorporate these methods into a clinical development workflow.


Praktiska nästa steg för utvecklingsteam

For teams actively assessing whether mild radical late-stage functionalization belongs in their modification strategy, the most productive near-term actions are:

  • Commission a small-scale feasibility run (5–10 mg) with the exact sequence, targeting the specific residue type, under the proposed radical conditions — with LC-HRMS characterization of the crude mixture, not just HPLC purity

  • Request stability data on the radical adduct bond under pH extremes, oxidativ stress, and thermal stress before designing a purification method

  • Map the impurity profile of the crude against what your preparative HPLC system can resolve, using spiked reference standards if available

  • Identify whether regulatory precedent for the catalyst or reagent class exists in published IND CMC summaries, FDA guidance documents, or EMA assessment reports

The chemistry is moving fast. The analytical and process development infrastructure to use it responsibly in a development program takes longer to build. Starting that construction now, on a well-defined target sequence, is the right approach.


MOL Ändringar supports development teams navigating complex modification requirements across more than 300 functional group transformation types, including click chemistry conjugation, glycopeptide synthesis, and isotope-labeled peptide production within a Class 100 sterile manufacturing environment. If your program involves modification positions or conjugation targets that fall outside standard SPPS workflows, a technical feasibility discussion is a practical starting point.

admin Avatar

Xiaoxia Chen

Nytt läkemedel R&D Tekniker Kärnexpertis: Målupptäckt, struktur-aktivitetsförhållande (SAR) analys, peptid-läkemedelskonjugat (PDCs), och utvecklingen av anti-aging och metabola peptider.

Profil: Xiaoxia Chen har lett den tidiga upptäckten och preklinisk forskning för flera metabola och tumörinriktade peptidläkemedel. Hon är inte bara skicklig i högkapacitetsscreening av peptidbibliotek utan också skicklig på att använda AI-assisterad beräkningsbiologi för de novo peptidsekvensdesign. För närvarande, hon leder ett team dedikerat till djupgående forskning och utveckling av nästa generations multifunktionella agonister (som dubbla- eller trippelmål-fettreducerande peptider) och högaktiva vävnadsreparationspeptider.

Fakta kontrollerat & Redaktionella riktlinjer
Recenserad av: Ämnesexperter
Dela den här artikeln
Hem Söka Whatsapp Tjänster Produkt